© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Biocon to go Ahead with Syngene IPO, Listing Likely in July
Posted 19th May 2015

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biotechnology major Biocon on Wednesday filed a prospectus with market regulator Securities and Exchange Board of India (Sebi) for the Initial Public Offer (IPO) of its research arm, Syngene, through which it aims to raise around Rs 600 crore for funding research and development (R&D).

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Biocon to go Ahead with Syngene IPO, Listing Likely in July

Biocon to go Ahead with Syngene IPO, Listing Likely in July

View Biography
Amarchand & Mangaldas

Biopharmaceuticals major Biocon on Tuesday said that the unlocking of the value from its contract research subsidiary Syngene would help the company fund its research and development programmes.

Syngene has already filed the draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), seeking approval for an initial public offering (IPO). The company is estimated to be raising around Rs 600 crore through this public issue.

“We are unlocking value from Syngene to fund our R&D programmes, which include a rich pipeline of biosimilars and novel biologics. This fund infusion will help accelerate these programmes which are at various stages of development currently,” said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon.

This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL), currently holds an 84.5 per cent equity stake in Syngene. The company is offering to sell up to 22 million equity shares of face value of Rs 10 each, through Syngene’s IPO.

The offer includes a reservation of two million equity shares for Biocon’s public equity shareholders, being individuals and Hindu Undivided Families (HUFs). The offer would constitute 11 per cent of the post offer paid-up equity share capital of the company.

Established in 1993, Syngene offers a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. The company’s service offerings also support the development of biosimilar and generic molecules.

During the nine months period-ended December 31, 2014, Syngene serviced 195 clients, ranging from multinational corporations to start-ups, including seven of the top 10 global pharmaceutical companies by sales for 2014.

Syngene had reported revenues of Rs 707.7 crore for the previous financial year-ended March 31, 2014 and Rs 617.5 crore for the nine months period ended December 31, 2014. Earlier this month, the company appointed Peter Bains as its Chief Executive Officer. Bains has been a part of Syngene since January 2010 as a director and has more than two decades of experience in the pharmaceutical space.

“Syngene has a proven track record of providing quality NME discovery, development and manufacturing services. It has long-standing partnerships with three of the world’s leading global healthcare organisations, including Bristol-Myers Squibb Co. and has attracted equity participation from India Value Fund recently, which is reflective of the scale, the value and the quality of the differentiated business model of Syngene,” added Mazumdar-Shaw.

Categories: Finance


You Might Also Like
Read Full PostRead - Eye Icon
Volatility and Complexity in Tax Rules
Legal
31/08/2016Volatility and Complexity in Tax Rules

AVELLUM is best known for its expertise in transactional tax and international tax planning. The firm’s unmatched experience allows us to provide clients with the best quality services in these fields.

Read Full PostRead - Eye Icon
What Is An ETF?
Finance
20/12/2018What Is An ETF?

Exchange Traded Funds, or ETFs as they are better known, are traded on a stock exchange, rather like a stock itself. Giving you a brief overview of this often overlooked or misunderstood asset class is Hannah Stevenson, Staff Writer here at Acquisition Interna

Read Full PostRead - Eye Icon
Attunity Acquire Appfluent for USD18m
Finance
Read Full PostRead - Eye Icon
Q1 Update – Mochtar Karuwin Komar
Strategy
01/07/2016Q1 Update – Mochtar Karuwin Komar

Mochtar Karuwin Komar (MKK) is one of Indonesia’s oldest firms and celebrates its 45th year in June 2016.

Read Full PostRead - Eye Icon
The Hidden Dangers of Blindly Embracing In Your Business
Innovation
27/04/2023The Hidden Dangers of Blindly Embracing In Your Business

It’s no secret that AI is a trending topic hot on many organisations’ agendas and strategies. However, with the release of ChatGPT, and Machine Learning continuously evolving, cybersecurity service providers, ramsac, are advising businesses not to blindly

Read Full PostRead - Eye Icon
Thinking Outside the Box
Leadership
13/08/2019Thinking Outside the Box

Rosenbaum IP is an outcome oriented intellectual property firm, specializing in IP portfolio asset value building. We caught up with AI’s Leading Complex Intellectual Property Attorney of the Year, Illinois and Rosenbaum IP’s Chairman & CEO, David G. Rosen

Read Full PostRead - Eye Icon
Who Are the Best UX Companies of 2025? 5 Top Options, Ranked
News
27/03/2025Who Are the Best UX Companies of 2025? 5 Top Options, Ranked

Who Are the Best UX Companies of 2025? 5 Best Options, Ranked User experience (UX) design is about more than the appearance of a website or product interface. Creating engaging experiences is what sets companies apart from the competition. A design that accoun

Read Full PostRead - Eye Icon
Pandora to Acquire Key Assets from Rdio
Innovation
17/11/2015Pandora to Acquire Key Assets from Rdio

Adding technology, IP and talent to accelerate development of new capabilities.

Read Full PostRead - Eye Icon
Family Business Owners are the Most Innovative, Study Finds
Finance
02/05/2018Family Business Owners are the Most Innovative, Study Finds

Family business owners are more innovative than owners of non-family businesses but are restricted by limited financial resources, says Dr Roberto Flören, Professor of Family Business at Nyenrode Business Universiteit.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow